4 stories mentioning SHE:002262Updated 10d ago
Every FINWIRES story that references SHE:002262, newest first.
Jiangsu Nhwa Pharmaceutical (SHE:002262) said its doxapram hydrochloride injection passed the generic drug quality and efficacy consistency evaluation of China's medical products regulator.The drug is used to treat respiratory failure, according to a Wednesday filing with the Shenzhen bourse.Shares of the pharmaceutical company closed 1% higher.
Authorities in Xuzhou, China, fined Jiangsu Nhwa Pharmaceutical (SHE:002262) 491,700 yuan for safety violations at a branch in Jiawang.The drug company's production exceeded permitted product types and its storage facilities went beyond their permitted scopes, according to a Tuesday filing with the Shenzhen bourse.Authorities also confirmed the drug company's compliance with correction orders.
Jiangsu Nhwa Pharmaceutical's (SHE:002262) attributable profit rose 5.6% to 317.4 million yuan in the first quarter from 300.7 million yuan in the year-ago period, according to a Saturday filing with the Shenzhen bourse.Earnings per share at the central nervous system drug manufacturer increased 3.3% to 0.31 yuan from 0.30 yuan in the prior-year period.Operating income grew 6.6% year over year to 1.61 billion yuan from 1.51 billion yuan.Shares decreased 6% during the midday break on Monday.
Jiangsu Nhwa Pharmaceutical's (SHE:002262) attributable profit fell 7.5% to 1.06 billion yuan in 2025 from 1.14 billion yuan in 2024, according to a Saturday filing with the Shenzhen bourse.Earnings per share at the central nervous system drug manufacturer decreased 7.1% to 1.05 yuan from 1.13 yuan in the previous year.Operating income grew 3.8% year over year to 5.91 billion yuan from 5.70 billion yuan.Shares decreased 6% during the midday break on Monday.
